YM116
YM116 is an orally active and competitive CYP17A1 (17,20-lyase) inhibitor (Ki: 0.38 nM) . YM116 reduces the synthesis of adrenal androgens by preferentially inhibiting C17-20 lyase activity. YM116 decreases the serum testosterone concentration, reduces dehydroepiandrosterone sulfate levels and decreases prostatic weights[1][2].
Product Specifications
CAS Number
183012-13-7
UNSPSC
12352005
Target
Cytochrome P450
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Endocrinology
Smiles
C1(NC2=C3C=CC=C2)=C3C=CC(CC4=CN=CN4)=C1
Molecular Formula
C16H13N3
Molecular Weight
247.29
References & Citations
[1]Ideyama Y, et al. Novel nonsteroidal inhibitor of cytochrome P450 (17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate. 1998 Sep 15;37 (1) :10-8.|[2]Ideyama Y, et al. YM116, 2- (1H-imidazol-4-ylmethyl) -9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79 (2) :213-20.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS649415-01 0.2 mL
ANKRD13C, NT (ANKRD13C, Ankyrin repeat domain-containing protein 13C)
Sign In for Pricing
View Details